"Jill brings to PDL more than 20 years of biopharmaceutical business development experience and an exceptional track-record of success spanning more than $3 billion in licensing and M&A transactions," said Mr. Monnet. "We look forward to her expertise in identifying opportunities and creating novel deal structures that support our goal of increasing shareholder value by expanding our portfolio of biopharmaceutical companies and products. Jill is exceptionally qualified to fill this critical position, and we are delighted to welcome her to PDL."
Dr. Jene previously served as senior vice president, business development at twoXAR, where she revamped the business development process, generated a pipeline of opportunities and negotiated deal terms for collaborations, spinouts and licenses. Previously, she was with Depomed for 11 years rising to vice president, business development.